The efficacy of alpelisib was recently evaluated in a Phase I trial in combination with olaparib in patients with recurrent ovarian cancer or TNBC, based on pre-clinical data showing that treatment with PI3K inhibitors may sensitize homologous recombination repair-proficient EOC tumors to PARP inhibition. This evidence concerns the gene PIK3CA and ovarian carcinoma.